

## Datasheet: MCA6145

**BATCH NUMBER 163316**

<b>Description:</b>	HUMAN ANTI C5 (ECULIZUMAB BIOSIMILAR)
<b>Specificity:</b>	C5
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	h5G1.1
<b>Isotype:</b>	IgG2/4
<b>Quantity:</b>	0.2 mg

### Product Details

#### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

<b>Target Species</b>	Human
<b>Product Form</b>	Human IgG2/4 (kappa) antibody - liquid
<b>Preparation</b>	Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line
<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	0.01% Thiomersal
<b>Approx. Protein Concentrations</b>	IgG concentration 1.0 mg/ml
<b>Immunogen</b>	Human C5
<b>Specificity</b>	<b>Human Anti-C5 alpha antibody, clone h5G1.1</b> , is a research grade biosimilar of the

monoclonal antibody drug eculizumab. It is a recombinant human IgG2/4 kappa antibody with variable regions from the therapeutic eculizumab antibody clone h5G1.1. This product is supplied in a research grade format, i.e. in PBS buffer with preservative, it is not manufactured or formulated in the same way as the therapeutic reference product. A preservative free version is available [on request](#).

Human Anti-C5 Antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-eculizumab antibodies for example HCA312 and HCA313.

Ecuzumab (Soliris) is a humanized IgG2/4 kappa antibody. The heavy chains are comprised of human IgG2 sequences in CH1, the hinge and the adjacent portion CH2, and human IgG4 sequences in the remaining part of CH2 and CH3. The drug is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired life-threatening disease of the blood characterized by destruction of red blood cells by the complement system. It also has approval as an orphan drug for treatment of atypical hemolytic uremic syndrome (aHUS). Ecuzumab specifically binds to the terminal complement component 5 (C5) and inhibits the cleavage of C5 to C5a and C5b by the C5 convertase, which prevents the generation of the terminal complement complex C5b-9. Both C5a and C5b-9 cause the terminal complement-mediated events that are characteristic of PNH and aHUS. A 1:1 molar ratio of ecuzumab to C5 is sufficient for C5 inhibition.

This product is NOT FOR THERAPEUTIC USE.

[View a summary of supporting anti-ecuzumab antibody products](#)

---

<b>Purity</b>	>98% by SDS PAGE
---------------	------------------

---

<b>Storage</b>	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.  Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
----------------	--

---

<b>Guarantee</b>	12 months from date of despatch
------------------	---------------------------------

---

<b>Acknowledgements</b>	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See <a href="http://bio-rad.com/en-us/trademarks">bio-rad.com/en-us/trademarks</a> for details.
-------------------------	--

---

<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10094 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA6145">https://www.bio-rad-antibodies.com/SDS/MCA6145</a> 10094
--------------------------------------	---

---

<b>Licensed Use</b>	For in vitro research purposes only. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
---------------------	--

---

## Related Products

### Recommended Useful Reagents

[HUMAN ANTI ECULIZUMAB \(HCA312\)](#)

[HUMAN ANTI ECULIZUMAB \(HCA313\)](#)

[HUMAN ANTI ECULIZUMAB:HRP \(HCA313P\)](#)

[HUMAN ANTI ECULIZUMAB \(HCA314\)](#)

[HUMAN ANTI ECULIZUMAB \(HCA315\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK001P\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)

'M400089:220707'

**Printed on 03 May 2024**

---